Skip to main content
. 2021 Mar 18;18(4):1491–1506. doi: 10.1021/acs.molpharmaceut.0c01238

Figure 2.

Figure 2

Physiological barriers to systemic delivery of RNA-based therapeutics. After systemic administration, the therapeutic nucleic acid must avoid interaction with bloodstream components, renal excretion, and uptake by phagocytes of the reticuloendothelial system (RES). Once at the targeted tissue, it must be internalized into the cell and escape from the endosome before degradation.